Navigation Links
Sanofi-aventis: Multaq(R) Approved in the European Union for Patients With Atrial Fibrillation
Date:11/30/2009

PARIS, November 30 /PRNewswire-FirstCall/ --

- First New Anti-Arrhythmic Drug to be Approved in the European Union in the Last 10 Years

Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that the European Commission has granted marketing authorization for Multaq(R) (dronedarone - 400mg Tablets) in all 27 European member states. This approval follows the European Commission positive opinion issued on September 25, 2009 by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicine agency (EMEA).

Multaq(R) is indicated in adult clinically stable patients with a history of, or current non-permanent atrial fibrillation (AF) to prevent recurrence of AF or to lower ventricular rate.

Multaq(R) discovered and developed by sanofi-aventis is the first anti-arrhythmic drug approved in the European Union that has shown a clinical benefit to reduce cardiovascular hospitalizations or death from any cause in patients with AF/AFL as described in the ATHENA trial.

"The approval of Multaq(R) in the European Union is important news for atrial fibrillation patients who will now have access to a new treatment approach," said Marc Cluzel, MD, Executive Vice President, Research and Development, sanofi-aventis. "The approval of Multaq(R) is the result of more than 15 years of research and development conducted by sanofi-aventis and supported by the commitment of the experts involved in the clinical development program and AF patients participating in the trials."

The use of dronedarone in unstable patients with NYHA class III and IV heart failure is contraindicated. Because of limited experience in stable patients with recent (1 to 3 months) NYHA class III heart failure or with Left Ventricular Ejection Fraction (LVEF) <35%, the use o
'/>"/>

SOURCE Sanofi-aventis
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation
2. ATHENA Clinical Results for Dronedarone (Multaq(R)) Highlighted at the World Cardiology Congress
3. ATHENA Clinical Results with Dronedarone (Multaq(R)) Highlighted at the World Cardiology Congress
4. Multaq(R) (dronedarone) Granted FDA Priority Review for Patients with Atrial Fibrillation
5. American Heart Journals Publishes Results From ERATO Trial Showing Dronedarone (Multaq(R)) Improves Ventricular Rate Control in Patients With Permanent Atrial Fibrillation
6. Further Analysis From ATHENA Study Showed That Multaq(R)(Dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation
7. Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation
8. Dronedarone (Multaq(R)) Reduced the Incidence and Duration of Hospitalization in Patients with Atrial Fibrillation
9. New England Journal of Medicine Publishes Results From the Landmark ATHENA Trial with Multaq(R) (dronedarone) in Atrial Fibrillation
10. FDA Advisory Committee Recommends Approval of Multaq(R) (dronedarone)
11. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... 28, 2014 Reportlinker.com announces that a ... catalogue: North America Laparoscopes Market Outlook ... North America Laparoscopes Market Outlook to ... America Laparoscopes Market Outlook to 2020", provides key ... The report provides value, in millions of US ...
(Date:8/28/2014)... 2014 /PRNewswire-iReach/ -- CountryFocus: Healthcare, Regulatory and Reimbursement ... (Photo - http://photos.prnewswire.com/prnh/20140828/140879 ) ... Reimbursement Landscape Poland " an essential source of ... healthcare market and provides insights into the demographic, ... the report provides valuable insights into the trends ...
(Date:8/28/2014)... China , Aug. 28, 2014 ... TPI ), a pharmaceutical company that specializes in ... generics and active pharmaceutical ingredients (API) today updates ... Company,s Qionglai Facility (QLF). The ... Practice (GMP) dataset for China Food & Drug ...
Breaking Medicine Technology:North America Laparoscopes Market Outlook to 2020 2North America Laparoscopes Market Outlook to 2020 3North America Laparoscopes Market Outlook to 2020 4North America Laparoscopes Market Outlook to 2020 5North America Laparoscopes Market Outlook to 2020 6North America Laparoscopes Market Outlook to 2020 7North America Laparoscopes Market Outlook to 2020 8North America Laparoscopes Market Outlook to 2020 9North America Laparoscopes Market Outlook to 2020 10North America Laparoscopes Market Outlook to 2020 11Poland & Turkey Pharmaceutical Market worth $15 billion & $21.5 billion Respectively by 2020 2Poland & Turkey Pharmaceutical Market worth $15 billion & $21.5 billion Respectively by 2020 3Poland & Turkey Pharmaceutical Market worth $15 billion & $21.5 billion Respectively by 2020 4Poland & Turkey Pharmaceutical Market worth $15 billion & $21.5 billion Respectively by 2020 5TPI Submits Dataset for GMP Inspection at Qionglai Facility (QLF) 2
... Reportlinker.com announces that a new market research ... Patient Self-Monitoring: Devices, Markets, Players ... http://www.reportlinker.com/p0581171/Patient-Self-Monitoring-Devices-Markets-Players-and-Prospects .html#utm_source=prnewswire&utm_medium=pr&utm_campaign=In_Vitro_Diagnostic The ... serum levels is deemed to be a ...
... A new patent covering tumor suppression technologies, including the ... awarded to The University of Texas System ... to the discovery that chromosome 3p21.3 genes act as ... also known as FUS1, the anti-cancer agent in ...
Cached Medicine Technology:Patient Self-Monitoring: Devices, Markets, Players and Prospects 2Patient Self-Monitoring: Devices, Markets, Players and Prospects 3Genprex Announces New Patent Issuance in Japan 2
(Date:8/28/2014)... Valero Renewable Fuels Company, LLC, a ... and the Ports of Indiana hosted Lt. Gov. Sue ... a Port Appreciation and Welcome Celebration commemorating the restart ... “The opening of Valero’s ethanol facility at the ... win for the State of Indiana,” Ellspermann said. “When ...
(Date:8/28/2014)... 2014 Gurnick Academy of Medical Arts ... is re-accredited for the 5 years of the accreditation ... (ARMRIT). , “We are very proud to have ... program to make sure we provide the best experience ... in MRI field nowadays and I look forward to ...
(Date:8/28/2014)... Norton HealthDay Reporter THURSDAY, ... sending electrical currents through the scalp to a specific network ... a day. In a small study of healthy young ... certain networks involved in memory. That, in turn, boosted participants, ... after the brain stimulation. During TMS, an electromagnetic coil ...
(Date:8/28/2014)... fermentation," when yeast that should be busily converting grape ... leaving the remaining sugar to instead be consumed by ... of researchers including UC Davis yeast geneticist Linda Bisson ... Working through a prion -- an abnormally shaped ... bacteria in fermenting wine to switch yeast from sugar ...
(Date:8/28/2014)... Chicago, IL (PRWEB) August 28, 2014 ... IT Supplement shows that while most hospitals utilize a ... of health care information technology is still a challenge. ... in the August issue of Health Affairs , ... Health Forum’s Health Care Data Center, as well as ...
Breaking Medicine News(10 mins):Health News:Valero, Ports of Indiana Celebrate Restart of Ethanol Plant 2Health News:Valero, Ports of Indiana Celebrate Restart of Ethanol Plant 3Health News:Gurnick Academy’s MRI Program Is Re-Accredited by ARMRIT for the 5 Years 2Health News:Electrical Pulses to Scalp May Boost Memory: Study 2Health News:Electrical Pulses to Scalp May Boost Memory: Study 3Health News:Prions can trigger 'stuck' wine fermentations, researchers find 2Health News:AHA Data Shows Progress, Challenges on Road to Healthcare IT Adoption 2Health News:AHA Data Shows Progress, Challenges on Road to Healthcare IT Adoption 3
... her down but along with her, her families too have to ... brain //and breast has taken its toll on Ellen who is ... the illness. Her family could seem to do nothing to ease ... quarters- the palliative care team at Dartmouth Hitchcock Medical Center. ...
... get married is a waste of breath, a US expert ... // ,William Smith, the vice president of the Sexuality, ... a six-year study commissioned by the US Congress found that ... on pushing sexual abstinence outside marriage had had no discernible ...
... day of reckoning is only getting closer for the Bush ... //The most recent, is the one cited by the American ... the information provided by the federally sponsored ‘Abstinence Only Sex ... way of a lengthy document compiled by Dr. John Santelli, ...
... ‘chemo brain’ that chemotherapy patients complain about, is finally ... especially women have for years informed their doctors about ... to concentrate, difficulty retrieving words, trouble with multitasking and ... edge. Once brushing such complaints aside, these very people, ...
... breakthrough method of blood test to diagnose Parkinson disease. This ... before the symptoms arrive. The test is done by a ... Melbourne University specialists. ,They have also created a ... it can screen many types of PD and monitor treatment ...
... is no evidence that antioxidant supplements interfere with ... a recent systematic //review of the use of ... increase survival rates, tumor response, and the patient’s ... implications for patients whose oncologists discourage the use ...
Cached Medicine News:Health News:The Pain Relieved With the Help of Palliative Workers 2Health News:Chemo Brain- Nothing Forgettable About It 2Health News:Chemo Brain- Nothing Forgettable About It 3Health News:New Blood Test to Diagnose Parkinson Disease 2Health News:Antioxidants May Aid Chemotherapy Patients 2